AstraZeneca and Bristol-Myers Squibb have announced the full results of the SAVOR clinical trial of Onglyza (saxagliptin…
Bristol-Myers Squibb
AstraZeneca and Bristol-Myers Squibb Resubmit New Type 2 Diabetes Treatment for FDA Approval
AstraZeneca and Bristol-Myers Squibb Company resubmitted a New Drug Application (NDA) to the U.S. FDA for the investigat…
Experimental Diabetes Drug Shows Improved Glycemic Control
A new study evaluating the efficacy and safety of adding dapagliflozin therapy to the treatment of type 2 diabetes patie…
FDA Requests Additional Data on Type 2 Diabetes Drug Dapagliflozin
The FDA has issued a complete response letter regarding the New Drug Application (NDA) for investigational compound dapa…
Type 2 Diabetes Drug ONGLYZA Approved for Sale in Europe
The European Commission has approved Bristol-Myers Squibb Company and AstraZeneca's ONGLYZA (saxagliptin) for use as a c…
Adding ONGLYZA to Insulin in Adults with Type 2 Diabetes Found Effective
Results of an investigational Phase 3b clinical study, presented by Bristol-Myers Squibb Company and AstraZeneca at the …
FDA Advisory Committee Votes Against Type 2 Diabetes Drug Dapagliflozin
The U.S. Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee meeting reached a de…
Type 2 Diabetes Drug, ONGLYZA, Approved for Treatment of Renal Impairment by EU
The European Commission approved a label update for ONGLYZA® (saxagliptin) in the treatment of adults with type 2 diabet…
Bristol-Myers Squibbs’ Dapagliflozin Demonstrated Improved Glycemic Control in Adults with Type 2 Diabetes
Bristol-Myers announced that findings from a 24-week Phase 3 clinical study, published online in the latest issue of Dia…
